Guozhong Yi

949 total citations
39 papers, 617 citations indexed

About

Guozhong Yi is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, Guozhong Yi has authored 39 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 16 papers in Molecular Biology and 14 papers in Cancer Research. Recurrent topics in Guozhong Yi's work include Glioma Diagnosis and Treatment (23 papers), Ferroptosis and cancer prognosis (10 papers) and Meningioma and schwannoma management (5 papers). Guozhong Yi is often cited by papers focused on Glioma Diagnosis and Treatment (23 papers), Ferroptosis and cancer prognosis (10 papers) and Meningioma and schwannoma management (5 papers). Guozhong Yi collaborates with scholars based in China and United States. Guozhong Yi's co-authors include Songtao Qi, Yawei Liu, Wei Xiang, Yaomin Li, Guanglong Huang, Shengze Deng, Hai Wang, Zhiyong Li, Guanglong Huang and Ziyang Chen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain and BioMed Research International.

In The Last Decade

Guozhong Yi

34 papers receiving 615 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guozhong Yi China 13 305 201 190 99 98 39 617
Xingli Dong China 12 391 1.3× 135 0.7× 201 1.1× 74 0.7× 75 0.8× 17 734
Anna‐Maria Barciszewska Poland 17 499 1.6× 178 0.9× 238 1.3× 68 0.7× 75 0.8× 34 733
Cristina Jiménez‐Luna Spain 14 333 1.1× 111 0.6× 171 0.9× 221 2.2× 65 0.7× 34 701
Katharine McNeill United States 4 163 0.5× 179 0.9× 107 0.6× 68 0.7× 66 0.7× 8 434
Lin Tang China 14 753 2.5× 152 0.8× 255 1.3× 72 0.7× 80 0.8× 51 1.1k
Huiming Yu China 13 432 1.4× 56 0.3× 334 1.8× 71 0.7× 83 0.8× 38 650
Kaijun Di United States 12 328 1.1× 164 0.8× 89 0.5× 113 1.1× 190 1.9× 26 603
Claudia Abbruzzese Italy 20 619 2.0× 107 0.5× 159 0.8× 134 1.4× 65 0.7× 36 950
Fenghua Lan China 15 384 1.3× 77 0.4× 137 0.7× 110 1.1× 123 1.3× 62 712
David L. Dai United States 15 356 1.2× 97 0.5× 119 0.6× 179 1.8× 86 0.9× 32 846

Countries citing papers authored by Guozhong Yi

Since Specialization
Citations

This map shows the geographic impact of Guozhong Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guozhong Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guozhong Yi more than expected).

Fields of papers citing papers by Guozhong Yi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guozhong Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guozhong Yi. The network helps show where Guozhong Yi may publish in the future.

Co-authorship network of co-authors of Guozhong Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Guozhong Yi. A scholar is included among the top collaborators of Guozhong Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guozhong Yi. Guozhong Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yi, Guozhong, et al.. (2025). Identification of the clinical and genetic characteristics of gliomas with gene fusions by integrated genomic and transcriptomic analysis. European journal of medical research. 30(1). 49–49. 1 indexed citations
2.
Qu, Shanqiang, et al.. (2025). The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐GlcNAcylation. CNS Neuroscience & Therapeutics. 31(8). e70546–e70546. 1 indexed citations
3.
Qu, Shanqiang, Zhi Ye, Qiuming Pan, et al.. (2025). Contemporary Precision Stratification and Prognostic Features of Primary Gliomas in a Southern Chinese Population. Research. 8. 1014–1014.
4.
Pan, Qiuming, Zhi Ting Ye, Junxi Wang, et al.. (2025). Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities. SHILAP Revista de lepidopterología. 3(3). 1 indexed citations
5.
Wang, Luyao, Ye Zhu, Qiuming Pan, et al.. (2025). Targeting ferroptosis in cancer stem cells: A novel strategy to improve cancer treatment. Genes & Diseases. 12(6). 101678–101678. 3 indexed citations
6.
7.
Qu, Shanqiang, Rongyang Xu, Guozhong Yi, et al.. (2024). Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine. Molecular Biomedicine. 5(1). 6–6. 34 indexed citations
8.
Que, Tianshi, Peidong Zhang, Zhiyong Li, et al.. (2023). Supramaximal resection based on en-bloc technique reduces tumor burden and prolongs survival in primary supratentorial lobar glioblastoma. Journal of Neuro-Oncology. 164(3). 557–568. 4 indexed citations
9.
Qu, Shanqiang, Kaicheng Wang, Luyao Wang, et al.. (2023). OLFML3, as a potential predictor of prognosis and therapeutic target for glioma, is closely related to immune cell infiltration. SHILAP Revista de lepidopterología. 4(2). 16 indexed citations
10.
Qu, Shanqiang, Songtao Qi, Zhiyong Li, et al.. (2023). Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. Journal of Experimental & Clinical Cancer Research. 42(1). 285–285. 20 indexed citations
11.
Li, Kaishu, Guanglong Huang, Ziyu Wang, et al.. (2022). IKBIP, a novel glioblastoma biomarker, maintains abnormal proliferation of tumor cells by inhibiting the ubiquitination and degradation of CDK4. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1869(1). 166571–166571. 8 indexed citations
12.
Zhang, Zhu, Haojie Zheng, Haiyan Xu, et al.. (2022). Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma. Cancer Cell International. 22(1). 151–151. 8 indexed citations
13.
Yang, Runwei, Haojie Zheng, Zhiyong Li, et al.. (2022). Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship. Clinical Neurology and Neurosurgery. 221. 107379–107379. 8 indexed citations
14.
Que, Tianshi, Zhiyong Li, Xi Yuan, et al.. (2022). Classification of unilateral thalamic gliomas predicts tumor resection and patient's survival: a single center retrospective study. Journal of Neurosurgical Sciences. 69(1). 111–122. 2 indexed citations
15.
Que, Tianshi, Haojie Zheng, Guozhong Yi, et al.. (2021). Ventricle wall resection contributes to supramaximal resection and prognosis in SVZ-involved frontal gliomas: A single center retrospective study. Clinical Neurology and Neurosurgery. 211. 107015–107015. 5 indexed citations
16.
17.
Guo, Jinglin, Guozhong Yi, Zhifeng Liu, et al.. (2019). Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide. Cell Biochemistry and Function. 38(2). 185–194. 7 indexed citations
18.
Yi, Guozhong, Guanglong Huang, Xian Zhang, et al.. (2019). Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain. 142(8). 2352–2366. 107 indexed citations
19.
Liu, Weiwen, Xian‐Lu Song, Shan‐Chao Zhao, et al.. (2017). Antitumor Activity and Mechanism of a Reverse Transcriptase Inhibitor, Dapivirine, in Glioblastoma. Journal of Cancer. 9(1). 117–128. 12 indexed citations
20.
Yi, Guozhong, et al.. (2016). Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. Journal of the Neurological Sciences. 367. 101–106. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xingli Dong Breakdown of academic impact, for papers by Anna‐Maria Barciszewska Breakdown of academic impact, for papers by Cristina Jiménez‐Luna Breakdown of academic impact, for papers by Katharine McNeill Breakdown of academic impact, for papers by Lin Tang Breakdown of academic impact, for papers by Huiming Yu Breakdown of academic impact, for papers by Kaijun Di Breakdown of academic impact, for papers by Claudia Abbruzzese Breakdown of academic impact, for papers by Fenghua Lan Breakdown of academic impact, for papers by David L. Dai
Rankless by CCL
2026